Key Points
- Insider purchase: On Dec 3 director Sarah Duncan bought 5,522 shares at GBX 71 each for a total of £3,920.62, signaling insider buying activity.
- Market snapshot: NIOX trades around GBX 71 (opened GBX 71.40), with a market cap of about £298.4m, a P/E of 57.12 and a 12‑month range of GBX 53.40–77.60.
- Business & recent results: NIOX is a medical‑technology company known for the NIOX VERO FeNO device serving 50+ countries; last quarter EPS was GBX 1.43 with a 13.29% ROE and 28.21% net margin, and analysts forecast roughly GBX 1.17 EPS for the year.
NIOX Group Plc (LON:NIOX - Get Free Report) insider Sarah Duncan bought 5,522 shares of the firm's stock in a transaction that occurred on Wednesday, December 3rd. The stock was bought at an average price of GBX 71 per share, for a total transaction of £3,920.62.
NIOX Group Trading Up 0.6%
Shares of LON NIOX opened at GBX 71.40 on Friday. The company has a quick ratio of 1.94, a current ratio of 6.31 and a debt-to-equity ratio of 1.10. NIOX Group Plc has a 12 month low of GBX 53.40 and a 12 month high of GBX 77.60. The company has a market cap of £298.37 million, a price-to-earnings ratio of 57.12 and a beta of 0.92. The business has a fifty day simple moving average of GBX 71.28 and a 200-day simple moving average of GBX 69.96.
NIOX Group (LON:NIOX - Get Free Report) last issued its quarterly earnings results on Tuesday, September 30th. The company reported GBX 1.43 earnings per share for the quarter. NIOX Group had a return on equity of 13.29% and a net margin of 28.21%. Sell-side analysts predict that NIOX Group Plc will post 1.1658256 EPS for the current year.
NIOX Group Company Profile
(
Get Free Report)
NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.
Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
